SCHEMBL10318093

SCHEMBL10318093

Cc1nnc(-c2ccc(Oc3cc(OC4CCNC4=O)cc(C(=O)Nc4nc5ccccc5s4)c3)cc2)o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.42
MEN1 O00255 6/20 0.42
RAB9A P51151 6/20 0.42
KMT2A Q03164 6/20 0.42
DHODH Q02127 1/20 0.42
SCD O00767 5/20 0.42
KDM4E B2RXH2 5/20 0.40
MAPT P10636 4/20 0.40
HTT P42858 3/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 1/20 0.40
TOP1 P11387 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
MAPKAPK2 P49137 1/20 0.38
KLF5 Q13887 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10320789 1.00 NPC1 (0.42) NPC1MEN1RAB9AKMT2ADHODH
SCHEMBL10318092 1.00 NPC1 (0.42) NPC1MEN1RAB9AKMT2ADHODH
SCHEMBL1271177 0.87 NPC1 (0.42) NPC1MEN1RAB9AKMT2ADHODH
SCHEMBL10317964 0.86 MAPT (0.46) MEN1RAB9AKMT2ASCDKDM4E
SCHEMBL10317965 0.86 MAPT (0.46) MEN1RAB9AKMT2ASCDKDM4E
SCHEMBL10318380 0.86 MAPT (0.46) MEN1RAB9AKMT2ASCDKDM4E
SCHEMBL10317278 0.85 SMN1; SMN2 (0.40) NPC1RAB9AALDH1A1SMN1; SMN2GCK
SCHEMBL10317618 0.85 SMN1; SMN2 (0.40) NPC1RAB9AALDH1A1SMN1; SMN2GCK
SCHEMBL10317280 0.85 SMN1; SMN2 (0.40) NPC1RAB9AALDH1A1SMN1; SMN2GCK
SCHEMBL10318557 0.85 GCK (0.47) GCKCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835469-B2 Substituted benzamide derivatives as glucokinase (GK) activators CADILA HEALTHCARE LIMITED (IN) 2014-09-16 US claimed
EP-2459554-B1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LTD (IN) 2013-09-18 EP claimed
US-8835469-B2 Substituted benzamide derivatives as glucokinase (GK) activators CADILA HEALTHCARE LIMITED (IN) 2014-09-16 US disclosed
EP-2459554-B1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LTD (IN) 2013-09-18 EP disclosed
US-20120184544-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184544-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS GCKR, GCK, GK NPC1 1459/4885MEN1 3511/4885RAB9A 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.